Acinic cell carcinoma classification
|
Acinic cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Acinic cell carcinoma classification On the Web |
|
American Roentgen Ray Society Images of Acinic cell carcinoma classification |
|
Risk calculators and risk factors for Acinic cell carcinoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
According to the 8th edition of American Joint Committee on Cancer(AJCC) and Union for International Cancer Control (UICC)the staging of salivary gland neoplasms are staged by TNM system.This means acinic cell carcinoma is staged based on tumor, node, and metastasis similar to squamous cell carcinoma.
Classification
According to the 8th edition of American Joint Committee on Cancer(AJCC) and Union for International Cancer Control (UICC)the staging of salivary gland neoplasms are staged by TNM system.[1] This means acinic cell carcinoma is staged based on tumor, node, and metastasis similar to squamous cell carcinoma.
| T category | N category | M category |
|---|---|---|
| TX: Primary tumor cannot be assessed | NX: Regional lymph nodes cannot be assessed | M0: No distant metastasis |
| T0: No evidence of primary tumor | N0: No regional lymph node metastasis | M1: Distant metastasis |
| Tis: Carcinoma in situ | N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(–) | |
| T1: Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension | N2:Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or
Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–); or Metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–); or In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(–) |
|
| T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension | N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or
A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(–) |
|
| T3: Tumor larger than 4 cm and/or tumor having extraparenchymal extension | N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(–) | |
| T4a: Moderately advanced disease.
Tumor invades skin, mandible, ear canal, and/or facial nerve. |
N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(–) | |
| T4b:Very advanced disease.
Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. |
N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–); or
In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or A single contralateral node of any size and ENE(+) |
|
| N3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(–) | ||
| N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or
Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or A single contralateral node of any size and ENE(+) |
References
- ↑ Son, Eugene; Panwar, Aru; Mosher, Charles H.; Lydiatt, Daniel (2018). "Cancers of the Major Salivary Gland". Journal of Oncology Practice. 14 (2): 99–108. doi:10.1200/JOP.2017.026856. ISSN 1554-7477.